MaxCyte (MXCT) Competitors $4.94 +0.19 (+4.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MXCT vs. PINC, CRTO, EVTC, RAMP, DFIN, ASTH, APLD, XMTR, NEO, and GDRXShould you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include Premier (PINC), Criteo (CRTO), EVERTEC (EVTC), LiveRamp (RAMP), Donnelley Financial Solutions (DFIN), Astrana Health (ASTH), Applied Digital (APLD), Xometry (XMTR), NeoGenomics (NEO), and GoodRx (GDRX). These companies are all part of the "business services" industry. MaxCyte vs. Premier Criteo EVERTEC LiveRamp Donnelley Financial Solutions Astrana Health Applied Digital Xometry NeoGenomics GoodRx MaxCyte (NASDAQ:MXCT) and Premier (NASDAQ:PINC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership. Does the media prefer MXCT or PINC? In the previous week, Premier had 1 more articles in the media than MaxCyte. MarketBeat recorded 7 mentions for Premier and 6 mentions for MaxCyte. Premier's average media sentiment score of 0.89 beat MaxCyte's score of 0.49 indicating that Premier is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Premier 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, MXCT or PINC? MaxCyte has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Premier has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Is MXCT or PINC more profitable? Premier has a net margin of 11.41% compared to MaxCyte's net margin of -78.36%. Premier's return on equity of 10.74% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets MaxCyte-78.36% -16.00% -13.93% Premier 11.41%10.74%6.36% Does the MarketBeat Community believe in MXCT or PINC? Premier received 602 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 68.19% of users gave Premier an outperform vote. CompanyUnderperformOutperformMaxCyteOutperform Votes1184.62% Underperform Votes215.38%PremierOutperform Votes61368.19% Underperform Votes28631.81% Do analysts recommend MXCT or PINC? MaxCyte presently has a consensus target price of $9.50, suggesting a potential upside of 92.31%. Premier has a consensus target price of $21.36, suggesting a potential downside of 4.78%. Given MaxCyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe MaxCyte is more favorable than Premier.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MaxCyte 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Premier 0 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders hold more shares of MXCT or PINC? 68.8% of MaxCyte shares are held by institutional investors. Comparatively, 74.4% of Premier shares are held by institutional investors. 3.0% of MaxCyte shares are held by company insiders. Comparatively, 1.0% of Premier shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, MXCT or PINC? Premier has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Premier, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxCyte$41.29M12.65-$37.92M-$0.34-14.53Premier$1.33B1.63$119.54M$1.3616.49 SummaryPremier beats MaxCyte on 11 of the 18 factors compared between the two stocks. Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MXCT vs. The Competition Export to ExcelMetricMaxCyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$522.21M$4.14B$5.21B$9.15BDividend YieldN/A1.82%5.13%4.03%P/E Ratio-14.5348.2588.0817.36Price / Sales12.6544.721,243.2778.03Price / CashN/A23.2643.7535.97Price / Book2.223.335.314.79Net Income-$37.92M$139.50M$122.62M$225.00M7 Day Performance0.61%-0.36%0.61%2.62%1 Month Performance16.51%-3.53%2.56%3.81%1 Year Performance-3.52%18.90%25.79%20.10% MaxCyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MXCTMaxCyte3.1014 of 5 stars$4.94+4.0%$9.50+92.3%-3.5%$522.21M$41.29M-14.5380PINCPremier1.8922 of 5 stars$21.33+2.2%$21.36+0.1%+1.5%$2.05B$1.33B15.682,900CRTOCriteo3.4084 of 5 stars$37.04+0.2%$50.67+36.8%+53.5%$2.04B$1.95B25.203,720Analyst DowngradeNews CoverageEVTCEVERTEC2.2897 of 5 stars$32.12+1.0%$35.00+9.0%-16.7%$2.04B$823.71M25.095,000Positive NewsRAMPLiveRamp4.2909 of 5 stars$29.24-0.3%$39.71+35.8%-20.4%$1.91B$707.17M584.921,400Gap UpDFINDonnelley Financial Solutions2.5768 of 5 stars$59.26+1.8%$76.33+28.8%+0.5%$1.71B$802.10M18.521,900Short Interest ↑ASTHAstrana Health3.8677 of 5 stars$30.28+2.7%$63.67+110.3%N/A$1.70B$1.72B23.291,800Short Interest ↓APLDApplied Digital3.2061 of 5 stars$7.77-6.3%$11.14+43.4%+83.1%$1.64B$189.96M-6.64121Earnings ReportShort Interest ↑Analyst RevisionGap UpXMTRXometry2.161 of 5 stars$32.92-1.8%$33.33+1.3%+1.3%$1.63B$525.13M-31.35790Gap DownNEONeoGenomics3.1159 of 5 stars$12.63-14.5%$20.30+60.7%-9.7%$1.62B$644.12M-20.702,100High Trading VolumeGDRXGoodRx4.2317 of 5 stars$4.22-7.3%$8.38+98.5%-28.9%$1.61B$790.39M-140.67950Short Interest ↓ Related Companies and Tools Related Companies Premier Alternatives Criteo Alternatives EVERTEC Alternatives LiveRamp Alternatives Donnelley Financial Solutions Alternatives Astrana Health Alternatives Applied Digital Alternatives Xometry Alternatives NeoGenomics Alternatives GoodRx Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MXCT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump secret stock already up 339% In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have a...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
